- Home » News and EventsPage 34
NEWS & EVENTS
Our newest offerings and capabilities. Recent investments in network capacity, new and expanded services and expertise. Upcoming conferences and events.
Catalent Recognized with 10 CMO Leadership Awards
Feb 5, 2018
Catalent Recognized with 10 CMO Leadership Awards. SOMERSET, N.J. – February 5, 2018 — Catalent Pharma Solutions, the leading global provider of advanced delivery technologies and development solution…
Catalent Biologics to Present at CASSS WCBP Symposium
Jan 29, 2018
SOMERSET, N.J. – January 29, 2018 — Catalent Pharma Solutions, the leading global provider of advanced delivery technologies and development solutions for drugs, biologics and consumer health products…
Triphase to Present IND Enabling Data for TRPH-222
Dec 4, 2017
Triphase to Present IND Enabling Data for TRPH-222. Toronto, Ontario, and Somerset, N.J. – December 4, 2017 – Triphase Accelerator Corporation, a company dedicated to acquiring and developing novel th…
Vaccinex and Catalent Biologics to Collaborate on ADC Development
Nov 30, 2017
Vaccinex and Catalent Biologics to Collaborate on ADC Development. – November 30, 2017 — Catalent Pharma Solutions, the leading global provider of advanced delivery technologies and development soluti…
Catalent Present on Drug Delivery, Formulation & Patient-Focused Design at AAPS
Nov 9, 2017
Catalent Present on Drug Delivery, Formulation & Patient-Focused Design at AAPS. SOMERSET, N.J. – November 9, 2017 — Catalent Pharma Solutions, the leading global provider of advanced delivery technol…
Catalent & Grid Collaborate to Develop Novel Targeted Immuno-Oncology Therapy
Oct 30, 2017
Catalent & Grid Collaborate to Develop Novel Targeted Immuno-Oncology Therapy. SOMERSET, N.J. – October 30, 2017 — Catalent Pharma Solutions, the leading global provider of advanced delivery technolog…
Catalent Completes Acquisition of Cook Pharmica
Oct 24, 2017
(NYSE: CTLT), the leading global provider of advanced delivery technologies and development solutions for drugs, biologics, and consumer health products, today announced it has completed the acquisiti…
FDA Approve Symbiomix’s Solosec™; Follows Four-Year Collaboration with Catalent
Oct 2, 2017
Catalent Pharma Solutions today welcomed Symbiomix Therapeutics’ announcement that the U.S. Food and Drug Administration (FDA) has approved Solosec™ (secnidazole) 2g oral granules for the treatment of…
Catalent to Host Workshops on Bioassay Development at Upcoming Conferences
Sep 25, 2017
Catalent Pharma Solutions today announced that two of its leading biologics analytical experts will be presenting workshops on the development and validation of bioassays at two upcoming conferences. …
No Results Found
The page you requested could not be found. Try refining your search, or use the navigation above to locate the post.